Advaxis Announces 2012 Annual Meeting of Stockholders
<0> Advaxis, Inc.Diana Moore, 609.452.9814Director, Investor Relations & Business DevelopmentorMedia:Russo PartnersMatt Middleman, M.D., 212-845-4272orDavid Schull, 212-845-4271 </0>
., a leader in developing the next generation of immunotherapies for cancer and infectious diseases,announced that its Annual Meeting of Stockholders will be held on Monday, August 13, 2012, at 10:00 a.m. EST at the D&R Greenway Land Trust, Johnson Education Center, One Preservation Place, Princeton, NJ 08540.
The meeting Agenda includes voting on proposals fully described in the 2012 Proxy Statement filed on July 9, 2012 and to transact any other business as may properly come before the Annual Meeting. Following the formal portion of the meeting, Thomas A. Moore, Chairman & CEO of Advaxis, will provide an update on Company progress including the status of the Advaxis clinical trial program and the Company’s future plans. A copy of the slides from Mr. Moore’s presentation will be available on the Company’s website following the meeting at .
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.
In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the .
Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neckcancer (CRUK study, Clinical Trials.gov Identifier NCT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the , , the , the , the , the , and others. For more information please visit: | |
.